| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Pancreaticoduodenectomy | 12 | 2022 | 92 | 2.930 |
Why?
|
| Pancreatic Neoplasms | 23 | 2025 | 685 | 2.680 |
Why?
|
| Drainage | 9 | 2021 | 257 | 2.110 |
Why?
|
| Carcinoma, Pancreatic Ductal | 13 | 2025 | 153 | 2.070 |
Why?
|
| Pancreatic Fistula | 5 | 2021 | 29 | 1.720 |
Why?
|
| Postoperative Care | 4 | 2019 | 295 | 1.410 |
Why?
|
| Postoperative Complications | 11 | 2021 | 3062 | 1.170 |
Why?
|
| Pancreatectomy | 10 | 2023 | 137 | 1.110 |
Why?
|
| Pancreas | 4 | 2023 | 217 | 0.880 |
Why?
|
| Adenocarcinoma | 7 | 2023 | 998 | 0.720 |
Why?
|
| Pancreatitis | 1 | 2020 | 130 | 0.650 |
Why?
|
| Choristoma | 1 | 2018 | 49 | 0.620 |
Why?
|
| Pancreatic Diseases | 1 | 2018 | 39 | 0.620 |
Why?
|
| Incidental Findings | 1 | 2018 | 124 | 0.590 |
Why?
|
| Spleen | 1 | 2018 | 280 | 0.580 |
Why?
|
| Clinical Protocols | 1 | 2018 | 235 | 0.570 |
Why?
|
| Nutritional Support | 1 | 2017 | 54 | 0.530 |
Why?
|
| Metabolic Diseases | 1 | 2017 | 129 | 0.490 |
Why?
|
| Antineoplastic Combined Chemotherapy Protocols | 5 | 2019 | 1240 | 0.480 |
Why?
|
| Colorectal Neoplasms | 7 | 2009 | 566 | 0.470 |
Why?
|
| Vascular Endothelial Growth Factor A | 5 | 2008 | 411 | 0.450 |
Why?
|
| Gastrointestinal Microbiome | 1 | 2020 | 693 | 0.430 |
Why?
|
| Pancreatitis, Chronic | 3 | 2023 | 68 | 0.420 |
Why?
|
| Liver Neoplasms, Experimental | 2 | 2009 | 61 | 0.400 |
Why?
|
| Receptors, Urokinase Plasminogen Activator | 1 | 2009 | 22 | 0.330 |
Why?
|
| Humans | 51 | 2025 | 124335 | 0.330 |
Why?
|
| Pancreatic Cyst | 2 | 2019 | 30 | 0.320 |
Why?
|
| Neoplasm Transplantation | 3 | 2021 | 374 | 0.320 |
Why?
|
| Neovascularization, Pathologic | 2 | 2008 | 240 | 0.310 |
Why?
|
| ErbB Receptors | 2 | 2019 | 286 | 0.300 |
Why?
|
| Liver Regeneration | 1 | 2008 | 38 | 0.300 |
Why?
|
| Health Status Disparities | 2 | 2025 | 227 | 0.300 |
Why?
|
| Prospective Studies | 8 | 2020 | 6083 | 0.300 |
Why?
|
| Jejunal Diseases | 1 | 2007 | 15 | 0.290 |
Why?
|
| Ileal Neoplasms | 1 | 2007 | 6 | 0.290 |
Why?
|
| Carcinoid Tumor | 1 | 2007 | 25 | 0.280 |
Why?
|
| Neoplasm Recurrence, Local | 1 | 2013 | 1127 | 0.280 |
Why?
|
| Cell Proliferation | 8 | 2019 | 2303 | 0.260 |
Why?
|
| Antibodies, Monoclonal | 2 | 2009 | 1015 | 0.260 |
Why?
|
| Aged | 17 | 2025 | 19461 | 0.260 |
Why?
|
| Intestinal Obstruction | 1 | 2007 | 97 | 0.260 |
Why?
|
| Middle Aged | 19 | 2025 | 26443 | 0.250 |
Why?
|
| Male | 25 | 2025 | 60990 | 0.250 |
Why?
|
| Retrospective Studies | 11 | 2022 | 16225 | 0.230 |
Why?
|
| Precancerous Conditions | 2 | 2019 | 283 | 0.230 |
Why?
|
| Tumor Microenvironment | 2 | 2025 | 549 | 0.220 |
Why?
|
| Female | 23 | 2025 | 66271 | 0.220 |
Why?
|
| Nitric Oxide | 1 | 2006 | 444 | 0.220 |
Why?
|
| Anastomosis, Surgical | 2 | 2021 | 168 | 0.220 |
Why?
|
| Mass Spectrometry | 2 | 2021 | 331 | 0.210 |
Why?
|
| RNA, Small Interfering | 3 | 2018 | 670 | 0.210 |
Why?
|
| Receptors, Vascular Endothelial Growth Factor | 3 | 2008 | 93 | 0.210 |
Why?
|
| Cell Line, Tumor | 9 | 2019 | 3342 | 0.210 |
Why?
|
| Quality of Life | 3 | 2023 | 1951 | 0.200 |
Why?
|
| Laparoscopy | 2 | 2020 | 489 | 0.190 |
Why?
|
| Amylases | 2 | 2019 | 26 | 0.190 |
Why?
|
| Cancer Vaccines | 1 | 2023 | 177 | 0.190 |
Why?
|
| Margins of Excision | 1 | 2021 | 51 | 0.180 |
Why?
|
| Biomedical Technology | 1 | 2021 | 36 | 0.180 |
Why?
|
| Heterografts | 1 | 2021 | 177 | 0.180 |
Why?
|
| Drug Resistance, Neoplasm | 3 | 2019 | 723 | 0.180 |
Why?
|
| Liver | 1 | 2008 | 1761 | 0.180 |
Why?
|
| Antineoplastic Agents | 4 | 2018 | 1674 | 0.180 |
Why?
|
| Follow-Up Studies | 5 | 2019 | 5107 | 0.170 |
Why?
|
| Pleural Neoplasms | 1 | 2020 | 48 | 0.170 |
Why?
|
| Mice, Nude | 3 | 2018 | 710 | 0.170 |
Why?
|
| Immunotherapy | 2 | 2023 | 662 | 0.170 |
Why?
|
| Cystadenoma, Serous | 1 | 2019 | 5 | 0.170 |
Why?
|
| Neoplasms | 2 | 2021 | 2794 | 0.160 |
Why?
|
| Device Removal | 2 | 2018 | 223 | 0.160 |
Why?
|
| Cell Movement | 6 | 2018 | 835 | 0.160 |
Why?
|
| Transforming Growth Factor alpha | 1 | 2019 | 27 | 0.160 |
Why?
|
| Tumor Suppressor Protein p53 | 2 | 2025 | 719 | 0.160 |
Why?
|
| Killer Cells, Natural | 1 | 2021 | 324 | 0.160 |
Why?
|
| HSP70 Heat-Shock Proteins | 1 | 2019 | 68 | 0.160 |
Why?
|
| Preservation, Biological | 1 | 2018 | 9 | 0.160 |
Why?
|
| Positron-Emission Tomography | 1 | 2020 | 298 | 0.160 |
Why?
|
| RNAi Therapeutics | 1 | 2018 | 17 | 0.160 |
Why?
|
| GPI-Linked Proteins | 1 | 2019 | 98 | 0.150 |
Why?
|
| Semaphorins | 2 | 2016 | 31 | 0.150 |
Why?
|
| Pathologists | 1 | 2018 | 29 | 0.150 |
Why?
|
| Diagnosis, Differential | 2 | 2018 | 1887 | 0.150 |
Why?
|
| Neuropilin-2 | 2 | 2008 | 9 | 0.150 |
Why?
|
| Radiologists | 1 | 2018 | 44 | 0.150 |
Why?
|
| Nutritional Status | 2 | 2019 | 312 | 0.150 |
Why?
|
| T-Lymphocytes, Cytotoxic | 1 | 2021 | 501 | 0.150 |
Why?
|
| Biological Specimen Banks | 1 | 2018 | 51 | 0.150 |
Why?
|
| Xenograft Model Antitumor Assays | 4 | 2021 | 887 | 0.150 |
Why?
|
| Mesenteric Veins | 1 | 2018 | 15 | 0.150 |
Why?
|
| Clinical Enzyme Tests | 1 | 2018 | 14 | 0.150 |
Why?
|
| Specimen Handling | 1 | 2018 | 140 | 0.150 |
Why?
|
| Random Allocation | 2 | 2009 | 436 | 0.150 |
Why?
|
| Organoplatinum Compounds | 2 | 2008 | 29 | 0.140 |
Why?
|
| Neoplasm Staging | 3 | 2020 | 1218 | 0.140 |
Why?
|
| Adult | 8 | 2020 | 29376 | 0.140 |
Why?
|
| Guidelines as Topic | 1 | 2018 | 198 | 0.140 |
Why?
|
| Non-Randomized Controlled Trials as Topic | 1 | 2017 | 13 | 0.140 |
Why?
|
| Evidence-Based Practice | 1 | 2018 | 114 | 0.130 |
Why?
|
| Combined Modality Therapy | 3 | 2017 | 1245 | 0.130 |
Why?
|
| Nuclear Receptor Coactivator 3 | 1 | 2018 | 348 | 0.130 |
Why?
|
| Treatment Outcome | 9 | 2019 | 12279 | 0.130 |
Why?
|
| Time-to-Treatment | 1 | 2018 | 187 | 0.130 |
Why?
|
| Transplantation, Heterologous | 3 | 2021 | 254 | 0.130 |
Why?
|
| Risk Factors | 6 | 2021 | 10137 | 0.130 |
Why?
|
| Venous Thrombosis | 1 | 2018 | 181 | 0.130 |
Why?
|
| Duodenal Neoplasms | 1 | 2016 | 21 | 0.130 |
Why?
|
| Mice | 9 | 2023 | 17734 | 0.130 |
Why?
|
| Proto-Oncogene Proteins c-ets | 1 | 2016 | 60 | 0.120 |
Why?
|
| Randomized Controlled Trials as Topic | 2 | 2018 | 1099 | 0.120 |
Why?
|
| Animals | 12 | 2023 | 34146 | 0.120 |
Why?
|
| Databases, Factual | 2 | 2018 | 1174 | 0.120 |
Why?
|
| Lymph Nodes | 1 | 2017 | 376 | 0.120 |
Why?
|
| Incidence | 4 | 2019 | 3086 | 0.120 |
Why?
|
| Evidence-Based Medicine | 1 | 2019 | 628 | 0.120 |
Why?
|
| Wnt Signaling Pathway | 1 | 2016 | 196 | 0.120 |
Why?
|
| Risk Assessment | 2 | 2021 | 3372 | 0.120 |
Why?
|
| Patient Care Team | 1 | 2018 | 546 | 0.120 |
Why?
|
| Surgeons | 1 | 2018 | 255 | 0.110 |
Why?
|
| Early Termination of Clinical Trials | 1 | 2014 | 16 | 0.110 |
Why?
|
| Malnutrition | 1 | 2017 | 203 | 0.110 |
Why?
|
| Neoplasm Invasiveness | 5 | 2018 | 606 | 0.110 |
Why?
|
| Tomography, X-Ray Computed | 2 | 2018 | 2087 | 0.110 |
Why?
|
| Bile Duct Diseases | 1 | 2013 | 17 | 0.110 |
Why?
|
| Bile | 1 | 2013 | 46 | 0.110 |
Why?
|
| Bevacizumab | 1 | 2013 | 63 | 0.110 |
Why?
|
| Deoxycytidine | 1 | 2013 | 76 | 0.110 |
Why?
|
| DNA Methylation | 1 | 2019 | 1000 | 0.100 |
Why?
|
| Radiotherapy Dosage | 1 | 2013 | 186 | 0.100 |
Why?
|
| Diabetes Mellitus, Type 1 | 1 | 2021 | 822 | 0.100 |
Why?
|
| Medical Oncology | 1 | 2014 | 215 | 0.100 |
Why?
|
| Remission Induction | 1 | 2013 | 301 | 0.100 |
Why?
|
| Practice Patterns, Physicians' | 1 | 2019 | 719 | 0.100 |
Why?
|
| Length of Stay | 2 | 2018 | 1306 | 0.100 |
Why?
|
| Erythrocyte Transfusion | 1 | 2013 | 128 | 0.100 |
Why?
|
| Gastroenterology | 1 | 2014 | 191 | 0.090 |
Why?
|
| Biomarkers | 2 | 2018 | 2976 | 0.090 |
Why?
|
| Preoperative Care | 1 | 2013 | 349 | 0.090 |
Why?
|
| Surgical Wound Infection | 1 | 2013 | 265 | 0.090 |
Why?
|
| Mutation | 3 | 2025 | 5806 | 0.090 |
Why?
|
| Healthcare Disparities | 1 | 2015 | 430 | 0.090 |
Why?
|
| Medically Uninsured | 1 | 2010 | 73 | 0.080 |
Why?
|
| Prognosis | 2 | 2023 | 4554 | 0.080 |
Why?
|
| Antibodies, Monoclonal, Humanized | 1 | 2013 | 504 | 0.080 |
Why?
|
| Liver Neoplasms | 2 | 2010 | 1319 | 0.080 |
Why?
|
| Gene Expression Regulation, Neoplastic | 3 | 2018 | 1900 | 0.080 |
Why?
|
| Inhibitor of Differentiation Protein 2 | 1 | 2008 | 3 | 0.080 |
Why?
|
| Receptor, IGF Type 1 | 1 | 2009 | 93 | 0.080 |
Why?
|
| Survival Rate | 1 | 2013 | 2020 | 0.080 |
Why?
|
| Injections, Intraperitoneal | 1 | 2008 | 73 | 0.080 |
Why?
|
| Disease-Free Survival | 2 | 2023 | 860 | 0.070 |
Why?
|
| DNA-Binding Proteins | 1 | 2016 | 2055 | 0.070 |
Why?
|
| Hepatectomy | 1 | 2008 | 110 | 0.070 |
Why?
|
| Jejunum | 1 | 2007 | 128 | 0.070 |
Why?
|
| Gastrointestinal Neoplasms | 1 | 2007 | 79 | 0.070 |
Why?
|
| Chemotherapy, Adjuvant | 2 | 2018 | 355 | 0.070 |
Why?
|
| Neoplastic Stem Cells | 1 | 2009 | 300 | 0.070 |
Why?
|
| Constriction, Pathologic | 1 | 2007 | 244 | 0.070 |
Why?
|
| Signal Transduction | 6 | 2019 | 4533 | 0.070 |
Why?
|
| Serotonin | 1 | 2007 | 232 | 0.060 |
Why?
|
| Nitric Oxide Synthase | 1 | 2006 | 186 | 0.060 |
Why?
|
| Mesoderm | 1 | 2006 | 113 | 0.060 |
Why?
|
| Mice, Inbred BALB C | 1 | 2008 | 1006 | 0.060 |
Why?
|
| Severity of Illness Index | 1 | 2014 | 2896 | 0.060 |
Why?
|
| Transcription Factors | 1 | 2016 | 2607 | 0.060 |
Why?
|
| Registries | 3 | 2019 | 1410 | 0.060 |
Why?
|
| Epithelium | 1 | 2006 | 361 | 0.060 |
Why?
|
| Tissue Array Analysis | 1 | 2025 | 137 | 0.060 |
Why?
|
| Chromosome Aberrations | 1 | 2007 | 621 | 0.060 |
Why?
|
| Survival Analysis | 2 | 2018 | 1482 | 0.060 |
Why?
|
| Frozen Sections | 1 | 2023 | 25 | 0.060 |
Why?
|
| Neoadjuvant Therapy | 2 | 2017 | 326 | 0.060 |
Why?
|
| 5'-Nucleotidase | 1 | 2023 | 16 | 0.050 |
Why?
|
| Observer Variation | 1 | 2023 | 302 | 0.050 |
Why?
|
| Time Factors | 3 | 2019 | 6263 | 0.050 |
Why?
|
| Adenosine | 1 | 2023 | 127 | 0.050 |
Why?
|
| Cell Survival | 2 | 2019 | 806 | 0.050 |
Why?
|
| Anti-Bacterial Agents | 1 | 2013 | 2417 | 0.050 |
Why?
|
| Common Bile Duct | 1 | 2021 | 14 | 0.050 |
Why?
|
| Carcinoma, Hepatocellular | 1 | 2010 | 938 | 0.050 |
Why?
|
| Parathyroidectomy | 1 | 2021 | 49 | 0.050 |
Why?
|
| Intraoperative Care | 1 | 2021 | 104 | 0.050 |
Why?
|
| Thyroid Gland | 1 | 2021 | 113 | 0.040 |
Why?
|
| Predictive Value of Tests | 2 | 2018 | 2122 | 0.040 |
Why?
|
| Interleukin-15 | 1 | 2021 | 91 | 0.040 |
Why?
|
| Statistics as Topic | 1 | 2021 | 254 | 0.040 |
Why?
|
| Bone Morphogenetic Protein 3 | 1 | 2019 | 1 | 0.040 |
Why?
|
| Cyst Fluid | 1 | 2019 | 6 | 0.040 |
Why?
|
| Carcinoembryonic Antigen | 1 | 2019 | 20 | 0.040 |
Why?
|
| Immunohistochemistry | 3 | 2008 | 1686 | 0.040 |
Why?
|
| Cetuximab | 1 | 2019 | 12 | 0.040 |
Why?
|
| Adjuvants, Immunologic | 1 | 2021 | 380 | 0.040 |
Why?
|
| Pyrimidinones | 1 | 2019 | 40 | 0.040 |
Why?
|
| Neoplasm Grading | 1 | 2019 | 266 | 0.040 |
Why?
|
| Cohort Studies | 2 | 2018 | 4730 | 0.040 |
Why?
|
| Proto-Oncogene Proteins p21(ras) | 1 | 2019 | 158 | 0.040 |
Why?
|
| T-Box Domain Proteins | 1 | 2019 | 121 | 0.040 |
Why?
|
| Radiotherapy, Adjuvant | 1 | 2018 | 142 | 0.040 |
Why?
|
| Pyridones | 1 | 2019 | 112 | 0.040 |
Why?
|
| Patient Reported Outcome Measures | 1 | 2019 | 171 | 0.040 |
Why?
|
| Tumor Burden | 1 | 2018 | 229 | 0.040 |
Why?
|
| Immunoprecipitation | 2 | 2008 | 199 | 0.040 |
Why?
|
| Apoptosis | 3 | 2009 | 1790 | 0.040 |
Why?
|
| Vascular Patency | 1 | 2018 | 213 | 0.040 |
Why?
|
| Mice, SCID | 1 | 2018 | 571 | 0.040 |
Why?
|
| Tumor Cells, Cultured | 1 | 2019 | 1064 | 0.030 |
Why?
|
| Blood Loss, Surgical | 1 | 2018 | 152 | 0.030 |
Why?
|
| Confidence Intervals | 1 | 2017 | 279 | 0.030 |
Why?
|
| Blood Glucose | 1 | 2021 | 1129 | 0.030 |
Why?
|
| Lymph Node Excision | 1 | 2017 | 157 | 0.030 |
Why?
|
| Cell Cycle | 1 | 2019 | 615 | 0.030 |
Why?
|
| Cell Nucleus | 1 | 2019 | 677 | 0.030 |
Why?
|
| Extracellular Signal-Regulated MAP Kinases | 1 | 2016 | 143 | 0.030 |
Why?
|
| Ampulla of Vater | 1 | 2016 | 16 | 0.030 |
Why?
|
| Lymphatic Metastasis | 1 | 2017 | 402 | 0.030 |
Why?
|
| Carcinogenesis | 1 | 2019 | 334 | 0.030 |
Why?
|
| Insulin | 1 | 2021 | 1207 | 0.030 |
Why?
|
| Polymerase Chain Reaction | 1 | 2019 | 1583 | 0.030 |
Why?
|
| Proteomics | 1 | 2019 | 489 | 0.030 |
Why?
|
| Microsatellite Repeats | 1 | 2016 | 219 | 0.030 |
Why?
|
| MAP Kinase Signaling System | 1 | 2016 | 314 | 0.030 |
Why?
|
| Reoperation | 1 | 2018 | 830 | 0.030 |
Why?
|
| Patient Readmission | 1 | 2018 | 377 | 0.030 |
Why?
|
| Sensitivity and Specificity | 1 | 2019 | 2029 | 0.030 |
Why?
|
| Genomic Instability | 1 | 2016 | 229 | 0.030 |
Why?
|
| Proportional Hazards Models | 1 | 2017 | 1320 | 0.030 |
Why?
|
| Molecular Diagnostic Techniques | 1 | 2014 | 150 | 0.030 |
Why?
|
| Hospital Mortality | 1 | 2018 | 1020 | 0.030 |
Why?
|
| Monitoring, Intraoperative | 1 | 2013 | 127 | 0.030 |
Why?
|
| Biomedical Research | 1 | 2018 | 518 | 0.030 |
Why?
|
| Surveys and Questionnaires | 1 | 2023 | 3731 | 0.030 |
Why?
|
| Reproducibility of Results | 1 | 2019 | 2871 | 0.030 |
Why?
|
| Antibiotic Prophylaxis | 1 | 2013 | 119 | 0.020 |
Why?
|
| Hemoglobins | 1 | 2013 | 306 | 0.020 |
Why?
|
| Molecular Targeted Therapy | 1 | 2014 | 353 | 0.020 |
Why?
|
| Drug Administration Schedule | 1 | 2013 | 725 | 0.020 |
Why?
|
| Precision Medicine | 1 | 2014 | 313 | 0.020 |
Why?
|
| Base Sequence | 1 | 2016 | 3093 | 0.020 |
Why?
|
| Perioperative Care | 1 | 2013 | 197 | 0.020 |
Why?
|
| Early Detection of Cancer | 1 | 2014 | 356 | 0.020 |
Why?
|
| Disease Models, Animal | 1 | 2021 | 4353 | 0.020 |
Why?
|
| Molecular Sequence Data | 1 | 2016 | 3873 | 0.020 |
Why?
|
| Patient Selection | 1 | 2014 | 688 | 0.020 |
Why?
|
| Diabetes Mellitus | 1 | 2018 | 853 | 0.020 |
Why?
|
| Aged, 80 and over | 1 | 2020 | 6467 | 0.020 |
Why?
|
| HT29 Cells | 1 | 2009 | 45 | 0.020 |
Why?
|
| AC133 Antigen | 1 | 2009 | 35 | 0.020 |
Why?
|
| Hyaluronan Receptors | 1 | 2009 | 66 | 0.020 |
Why?
|
| Serrate-Jagged Proteins | 1 | 2008 | 38 | 0.020 |
Why?
|
| Vascular Endothelial Growth Factor B | 1 | 2008 | 7 | 0.020 |
Why?
|
| Vascular Endothelial Growth Factor C | 1 | 2008 | 9 | 0.020 |
Why?
|
| Autoradiography | 1 | 2008 | 71 | 0.020 |
Why?
|
| Placenta Growth Factor | 1 | 2008 | 11 | 0.020 |
Why?
|
| Fluorouracil | 1 | 2009 | 128 | 0.020 |
Why?
|
| Jagged-1 Protein | 1 | 2008 | 53 | 0.020 |
Why?
|
| Pregnancy Proteins | 1 | 2008 | 13 | 0.020 |
Why?
|
| Culture Media, Conditioned | 1 | 2008 | 79 | 0.020 |
Why?
|
| Half-Life | 1 | 2008 | 156 | 0.020 |
Why?
|
| Neuropilin-1 | 1 | 2007 | 15 | 0.020 |
Why?
|
| HCT116 Cells | 1 | 2008 | 55 | 0.020 |
Why?
|
| Cell Hypoxia | 1 | 2008 | 95 | 0.020 |
Why?
|
| Vascular Endothelial Growth Factor Receptor-1 | 1 | 2008 | 42 | 0.020 |
Why?
|
| Immunoblotting | 1 | 2008 | 313 | 0.020 |
Why?
|
| Kaplan-Meier Estimate | 1 | 2010 | 1017 | 0.020 |
Why?
|
| Calcium-Binding Proteins | 1 | 2008 | 324 | 0.020 |
Why?
|
| Intercellular Signaling Peptides and Proteins | 1 | 2008 | 280 | 0.020 |
Why?
|
| Liposomes | 1 | 2008 | 169 | 0.020 |
Why?
|
| Antigens, CD | 1 | 2009 | 421 | 0.020 |
Why?
|
| Glycoproteins | 1 | 2009 | 369 | 0.020 |
Why?
|
| Spindle Apparatus | 1 | 2006 | 63 | 0.020 |
Why?
|
| Blotting, Western | 1 | 2008 | 1109 | 0.020 |
Why?
|
| Flow Cytometry | 1 | 2008 | 802 | 0.020 |
Why?
|
| Hepatitis C, Chronic | 1 | 2010 | 324 | 0.020 |
Why?
|
| Up-Regulation | 1 | 2008 | 862 | 0.020 |
Why?
|
| Transfection | 1 | 2008 | 1069 | 0.020 |
Why?
|
| Peptides | 1 | 2009 | 793 | 0.020 |
Why?
|
| Cadherins | 1 | 2006 | 165 | 0.020 |
Why?
|
| Carcinoma | 1 | 2008 | 281 | 0.020 |
Why?
|
| Proto-Oncogene Proteins c-akt | 1 | 2008 | 488 | 0.020 |
Why?
|
| Reverse Transcriptase Polymerase Chain Reaction | 1 | 2008 | 1289 | 0.010 |
Why?
|
| Neoplasm Metastasis | 1 | 2006 | 662 | 0.010 |
Why?
|
| Transcription, Genetic | 1 | 2008 | 1701 | 0.010 |
Why?
|
| RNA, Messenger | 1 | 2008 | 2824 | 0.010 |
Why?
|
| Disease Progression | 1 | 2008 | 2038 | 0.010 |
Why?
|
| Texas | 1 | 2010 | 3590 | 0.010 |
Why?
|
| Membrane Proteins | 1 | 2008 | 1530 | 0.010 |
Why?
|
| United States | 1 | 2015 | 10766 | 0.010 |
Why?
|
| Phenotype | 1 | 2009 | 4257 | 0.010 |
Why?
|
| Child | 1 | 2018 | 24516 | 0.010 |
Why?
|